Corium Appoints Perry Sternberg as Chief Executive Officer
April 02 2019 - 4:30PM
Corium, Inc. announced today that its Board of Directors has named
Perry Sternberg as Chief Executive Officer. Mr. Sternberg is
a senior pharmaceutical executive with commercial experience across
a wide range of therapeutic areas in diverse markets. He most
recently served a dual role at Shire Plc as the Head of U.S.
Commercial for seven therapeutic area business units, as well as
the Chief Commercial Officer/Head of the Neuroscience Division,
before the recent acquisition of Shire by Takeda Pharmaceutical
Corporation Limited. He brings more than 25 years of
experience in the pharmaceutical and biotechnology industries with
direct responsibility for the launch and commercialization of more
than twenty products over the course of his career. Mr.
Sternberg will succeed Peter Staple, who has served as Corium’s
Chief Executive Officer since 2008 and will continue his
involvement with the company as Chairman of its Board of
Directors.
“I’m very excited to welcome Perry to lead Corium into the next
major phase of our development,” said Mr. Staple. “He brings
years of demonstrated launch success across a variety of
therapeutic areas. Perry is uniquely qualified to step into
the leadership role and build out the organization to commercialize
our own products, starting with our lead Corplex™ Donepezil
candidate for Alzheimer’s patients, and help guide the development
of Corium’s pipeline.”
“I am honored to be joining the Corium team at such an important
point in its history, and look forward to building on its strengths
in developing and manufacturing innovative transdermal products,”
said Mr. Sternberg. “Based on Corium’s pipeline of products
in development, as well as the financial backing and deep industry
expertise the company has from Gurnet Point Capital, we have a
clear opportunity to accelerate the growth of the company and meet
the needs of patients and their families.”
Before joining Shire in 2013, Mr. Sternberg served as the Vice
President and General Manager of U.S. and Canada Pharmaceuticals at
Bausch & Lomb. He started his pharmaceutical industry career at
Merck & Co, Inc. as a sales representative and moved on to hold
a series of sales and marketing roles of increasing scope at Merck
& Co, Inc., Novartis Pharmaceuticals, Novartis Ophthalmics and
Bausch & Lomb. Mr. Sternberg’s career therapeutic expertise has
spanned across neuroscience, ophthalmics, osteoporosis,
cardiovascular, genitourinary and rare diseases.
About Corium
Corium, Inc. is a commercial-stage biopharmaceutical company
focused on the development, manufacture and commercialization of
specialty pharmaceutical products that leverage the company's broad
experience with advanced transdermal and transmucosal delivery
systems. Corium has multiple proprietary programs in
preclinical and clinical development, focusing primarily on the
treatment of neurological disorders, with lead programs in
Alzheimer's disease. Corium has developed and is the sole
commercial manufacturer of seven prescription drug and consumer
products with partners Mayne Pharma and Procter & Gamble.
The company has two proprietary transdermal platforms: Corplex™ for
small molecules and MicroCor®, a biodegradable microstructure
technology for small molecules and biologics, including vaccines,
peptides and proteins. In November, 2018, all of Corium’s
outstanding stock was acquired by an affiliate of Gurnet Point
Capital. For further information, please visit
www.coriumintl.com.
About Gurnet Point Capital
Gurnet Point Capital is a unique healthcare fund founded
by Ernesto Bertarelli and led by Chris Viehbacher,
who, together, have decades of expertise in an industry for which
they share a passion, both as Chief Executives and as investors.
With an initial allocation of $2 billion, GPC is
investing long-term capital and supporting entrepreneurs in
building a new generation of companies. Based in Cambridge,
MA, its remit is global, encompassing life sciences and medical
technologies. The fund invests across all stages of product
development through to commercialization and does so with an
approach that is a hybrid of venture and private equity investing
strategies. www.gurnetpointcapital.com
Corplex™ and MicroCor® are registered trademarks of Corium,
Inc.
Investor and Media Contact:SMP CommunicationsSusan M.
Pietropaolosusan@smpcommunications.com(201) 923-2049
Source: Corium, Inc.
CORIUM INTERNATIONAL, INC. (NASDAQ:CORI)
Historical Stock Chart
From Mar 2024 to Apr 2024
CORIUM INTERNATIONAL, INC. (NASDAQ:CORI)
Historical Stock Chart
From Apr 2023 to Apr 2024